BIDMC Research & Education
@bidmcreseach.bsky.social
Official channel for news and information about research publication and medical education across Beth Israel Deaconess Medical Center
BIDMC.org
BIDMC.org
In @jamacardiology.com , scientists show nearly 6 in 10 US vs 3 in 10 Japanese older adults with diabetes quit semaglutide shots w/in 1 year. Lower discontinuation in Japan points to impact of costs, supply issues jamanetwork.com/journals/jam...
Discontinuation of Semaglutide Among Older Adults With Diabetes in the US and Japan
This cohort study evaluates frequencies and predictors of discontinuation of injectable semaglutide in older adults with diabetes in the US and Japan.
jamanetwork.com
September 25, 2025 at 3:47 PM
In @jamacardiology.com , scientists show nearly 6 in 10 US vs 3 in 10 Japanese older adults with diabetes quit semaglutide shots w/in 1 year. Lower discontinuation in Japan points to impact of costs, supply issues jamanetwork.com/journals/jam...
Reposted by BIDMC Research & Education
💻 #AI & #MachineLearning for Sepsis Diagnosis
Researchers at Prenosis, @bidmcreseach.bsky.social & @harvardmed.bsky.social developed the Sepsis ImmunoScore, an AI tool that predicts patient risk & severity within 24 hours.
Learn more in @ai.nejm.org
ai.nejm.org/doi/full/10....
5/
Researchers at Prenosis, @bidmcreseach.bsky.social & @harvardmed.bsky.social developed the Sepsis ImmunoScore, an AI tool that predicts patient risk & severity within 24 hours.
Learn more in @ai.nejm.org
ai.nejm.org/doi/full/10....
5/
FDA-Authorized AI/ML Tool for Sepsis Prediction: Development and Validation
Sepsis is a life-threatening condition that demands prompt treatment for improved
patient outcomes. Its heterogenous presentation makes early detection challenging,
highlighting the need for effect...
ai.nejm.org
September 25, 2025 at 12:58 PM
💻 #AI & #MachineLearning for Sepsis Diagnosis
Researchers at Prenosis, @bidmcreseach.bsky.social & @harvardmed.bsky.social developed the Sepsis ImmunoScore, an AI tool that predicts patient risk & severity within 24 hours.
Learn more in @ai.nejm.org
ai.nejm.org/doi/full/10....
5/
Researchers at Prenosis, @bidmcreseach.bsky.social & @harvardmed.bsky.social developed the Sepsis ImmunoScore, an AI tool that predicts patient risk & severity within 24 hours.
Learn more in @ai.nejm.org
ai.nejm.org/doi/full/10....
5/
Reposted by BIDMC Research & Education
Scientists, academics, researchers: We’re excited to share that @altmetric.com is now tracking mentions of your research on Bluesky! 🧪
There are already many articles for which there is more attention on Bluesky than on other comparable micro-blogging sites, meaning the academic community and the general public have clearly adopted Bluesky as one of its core places to disseminate and discuss new research.
A Place of Joy.
A Place of Joy.
December 3, 2024 at 2:10 PM
Scientists, academics, researchers: We’re excited to share that @altmetric.com is now tracking mentions of your research on Bluesky! 🧪
BIDMC's Brian J. Carney, MD, and Richard L. Haspel, MD, & colleague describe how non-evidenced based policies regarding people with sickle cell trait can lead to unequal treatment in the US military and college athletics and beyond.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Sickle Cell Trait, Inequity, and the Need for Change | NEJM
Because of misperceptions about risks, people with sickle cell trait in the United
States may receive inequitable and potentially harmful treatment, with implications
for autonomy, privacy, and ...
www.nejm.org
December 3, 2024 at 9:53 PM
BIDMC's Brian J. Carney, MD, and Richard L. Haspel, MD, & colleague describe how non-evidenced based policies regarding people with sickle cell trait can lead to unequal treatment in the US military and college athletics and beyond.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
“Ensuring equitable access to these effective but high-cost medications, and supporting individuals so that they can stay on the therapy long-term, should be a priority for our clinicians and policymakers." said corresponding author Dhruv S. Kazi, MD, MS,
www.bidmc.org/about-bidmc/...
www.bidmc.org/about-bidmc/...
More Than Half of U.S. Adults Could Benefit from GLP-1 Medications, Researchers Find | BIDMC of Boston
BIDMC researchers find that 137 million adults are eligible for semagludtide for weight loss, diabetes management or recurrent cardiovascular event prevention.
www.bidmc.org
December 3, 2024 at 8:24 PM
“Ensuring equitable access to these effective but high-cost medications, and supporting individuals so that they can stay on the therapy long-term, should be a priority for our clinicians and policymakers." said corresponding author Dhruv S. Kazi, MD, MS,
www.bidmc.org/about-bidmc/...
www.bidmc.org/about-bidmc/...
Reposted by BIDMC Research & Education
"Authoritative tips for manuscript preparation" #Matter
Edward Sargent shares ten tips on writing successful research articles.
Open Access
www.cell.com/matter/fullt...
Edward Sargent shares ten tips on writing successful research articles.
Open Access
www.cell.com/matter/fullt...
December 3, 2024 at 2:42 PM
"Authoritative tips for manuscript preparation" #Matter
Edward Sargent shares ten tips on writing successful research articles.
Open Access
www.cell.com/matter/fullt...
Edward Sargent shares ten tips on writing successful research articles.
Open Access
www.cell.com/matter/fullt...
Reposted by BIDMC Research & Education
Viewpoint from Sven Jordt and Sairam Jabba: California's Assembly Bill 3218 closes loopholes on flavored tobacco and synthetic nicotine, setting a potential model for other states and the FDA.
ja.ma/4eXuHza
ja.ma/4eXuHza
December 3, 2024 at 8:18 PM
Viewpoint from Sven Jordt and Sairam Jabba: California's Assembly Bill 3218 closes loopholes on flavored tobacco and synthetic nicotine, setting a potential model for other states and the FDA.
ja.ma/4eXuHza
ja.ma/4eXuHza